Cytosorbents Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
2analysts covering
FY Revenue (est.)
$38.9Mnext fiscal year
FY EPS (est.)
-$0.22next fiscal year
Monitoring Framework
Key Performance Indicators
Total Revenue Annually37.1M
Gross Margin Quarterly71.0%Target: 73-75%
Operating Cash Flow Breakeven QuarterlyTarget: Breakeven in H2 2026
Watch Items
- FDA De Novo Application for DrugSorb-ATRTrigger: Submission of new De Novo applicationAction: Monitor pre-submission meetings and alignment on mechanistic data expected in late 2026 or early 2027.
- Nasdaq Minimum Bid Price ComplianceTrigger: Share price below $1.00Action: Track shareholder vote on the proposed 1-for-5 to 1-for-20 reverse stock split at the August 13, 2026 Annual Meeting to maintain listing before the September 28, 2026 deadline.
Research as of 19 Jun 2026